PGxCare offers an AI capabilities, enabling analysis of pharmacogenetic data ensuring accurate results tailored to individual needs.
PGxCare has raised $1.5M in total funding. The most recent round was Seed. The last funding was announced in March 2024.
PGxCare's investors include Roman Smolevskiy, ATEM Capital Fund LP.
PGxCare is headquartered in Palo Alto, United States.
PGxCare offers an AI capabilities, enabling analysis of pharmacogenetic data ensuring accurate results tailored to individual needs.
PGxCare is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"PGxCare — Funding & Investors." VCBacked, March 19, 2024, https://www.vcbacked.co/company/pgxcare. Accessed September 30, 2026.
VCBacked. (2024). PGxCare — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/pgxcare
{{cite web |title=PGxCare — Funding & Investors |url=https://www.vcbacked.co/company/pgxcare |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated